Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Related News
Breakthrough in gastric cancer
Source: Xinhua |
April 24, 2009, Friday
|
Print Edition
Print Edition
CHINA has developed the world's first oral vaccine for bacteria that are closely linked to gastric cancer, the Ministry of Science and Technology said yesterday.
The vaccine is designed to prevent infection by Helicobacter pylori, bacteria that inhabit parts of the stomach and are believed to be strongly linked to the development of duodenal and gastric ulcers and even stomach cancer.
The ministry said the drug is the world's first Hp vaccine to finish large-scale phase-three clinical trials and become ratified as a new medicine.
The vaccine has been classified as a "first-grade new medicine" by the State Food and Drug Administration, China's drug watchdog.
It was developed by a research team from the Chongqing-based Third Military Medical University headed by professor Zou Quanming after 15 years of effort, the university's president, Wang Denggao, told a news conference.
During the research process, the vaccine secured eight national patents and now has full independent intellectual property rights, Wang said.
Clinical research showed that the vaccine has a protection rate of more than 72.1 percent against Hp bacteria, he said.
The ministry said researchers and investors would increase cooperation to commercialize the vaccine at an early date. China now has 600 million people infected by Hp, and some 200,000 die from stomach cancer every year.
The vaccine is designed to prevent infection by Helicobacter pylori, bacteria that inhabit parts of the stomach and are believed to be strongly linked to the development of duodenal and gastric ulcers and even stomach cancer.
The ministry said the drug is the world's first Hp vaccine to finish large-scale phase-three clinical trials and become ratified as a new medicine.
The vaccine has been classified as a "first-grade new medicine" by the State Food and Drug Administration, China's drug watchdog.
It was developed by a research team from the Chongqing-based Third Military Medical University headed by professor Zou Quanming after 15 years of effort, the university's president, Wang Denggao, told a news conference.
During the research process, the vaccine secured eight national patents and now has full independent intellectual property rights, Wang said.
Clinical research showed that the vaccine has a protection rate of more than 72.1 percent against Hp bacteria, he said.
The ministry said researchers and investors would increase cooperation to commercialize the vaccine at an early date. China now has 600 million people infected by Hp, and some 200,000 die from stomach cancer every year.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
